Vertical: CNMBase Year: 2025
Market Size (2025)
$182.29M
Projected (2032)
$257.76M
CAGR (2022–2032)
5.1%
Key Players
9+
Market Overview
The global monensin market was valued at USD 182.30 million in 2025 and is projected to reach USD 257.76 million by 2032, registering a CAGR of 5.07% over 2026–2032. In absolute terms, the market is expected to add USD 75.46 million in value between 2025 and 2032. The market grew from USD 157.10 million in 2022, and is forecast to reach USD 191.55 million in 2026.
Monensin is a polyether ionophore produced by fermentation of Streptomyces cinnamonensis and is used almost exclusively in animal production. In poultry, it is one of the most established in-feed coccidiostats for broilers, replacement pullets and turkeys. In cattle, it alters rumen fermentation towards propionate, improving feed efficiency, and is used for the prevention and control of coccidiosis, the reduction of bloat and, in dairy cows, the improvement of milk production efficiency. Because ionophores have no use in human medicine, monensin occupies a distinct regulatory position: it remains available over the counter in the United States and several other markets, even as medically important antimicrobials face tighter controls.
Key Findings
By Livestock: Cattle was the largest segment in 2025 at USD 100.26 million (55.0% share) and is also the fastest-growing segment, with a CAGR of 5.47% over 2026–2032. Poultry accounted for USD 82.03 million (45.0%).
By Physical Form: Premix dominated with USD 154.95 million (85.0% share) in 2025, while Others is the fastest-growing form, with a CAGR of 6.08%.
By Region: North America and Asia Pacific were jointly the leading regions in 2025, each valued at USD 54.69 million (30.0% share each). Asia Pacific moves ahead from 2026 onwards and is the fastest-growing region, with a CAGR of 6.14%, reaching USD 82.87 million by 2032.
By Country: The U.S. was the leading country market in 2025 at USD 42.66 million (23.4% of the global market). India is the fastest-growing country, with a CAGR of 7.87% over 2026–2032.
Segmentation Summary
The market is analysed by livestock (Cattle and Poultry), by physical form (Premix and Others) and by region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa), with country-level data for 20 country and sub-regional markets. Cattle holds the majority of value because monensin is used across beef feedlots, stocker and pasture systems, dairy herds and replacement heifers, while poultry use is concentrated in coccidiosis prevention for broilers, pullets and turkeys. Premix remains the standard commercial format, since monensin is overwhelmingly delivered through compound feed; Others, which covers granular Type A articles, liquid feed supplements, free-choice blocks and intraruminal devices, is growing faster at 6.08% as pasture-based delivery options widen.
Competitive Landscape Summary
The supply of monensin is concentrated at the fermentation and active-ingredient level. Elanco Animal Health, the originator of the Rumensin and Coban brands, remains the reference supplier worldwide. Huvepharma, through its Bulgarian fermentation base, is the principal generic competitor and gained the first U.S. generic approval for monensin in 2019 with Monovet 90. Phibro Animal Health supplies monensin in Australia and New Zealand and holds a U.S. combination approval with Rumensin. Downstream, feed and supplement companies such as Ridley USA (Alltech), ADM Animal Nutrition and Purina Animal Nutrition hold approvals for medicated free-choice products, while Chinese fermentation companies supply monensin active ingredient to Asian markets.
Challenges and Opportunities
The main challenges are the acute toxicity of monensin to horses and dogs, which makes feed-mill cross-contamination a serious liability risk; consumer-led antibiotic-free poultry programmes that exclude ionophores; restricted use in European cattle; reduced Eimeria sensitivity after long use; and price pressure from generic supply. Opportunities lie in the intensification of cattle and poultry production in Asia Pacific and Latin America, the growing evidence base for monensin as a practical enteric methane mitigation tool, and new delivery formats and combination approvals that extend monensin into pasture, heifer-rearing and dairy systems.
Future Outlook
Demand is expected to rise steadily through 2032, supported by record global chicken meat output and the continued economic value of feed efficiency in cattle. Growth will be faster in Asia Pacific (6.14%) and Latin America (5.62%) than in North America (4.09%) and Europe (3.58%). Suppliers that combine reliable fermentation capacity, strong regulatory files and evidence on sustainability outcomes are best placed to capture this growth.
The Monensin Market market is projected to grow at a CAGR of 5.1% from 2022 to 2032.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansDefinition
Monensin is a carboxylic polyether ionophore antibiotic produced by fermentation of Streptomyces cinnamonensis and marketed mainly as monensin sodium. It forms lipid-soluble complexes with monovalent cations such as sodium and potassium and transports them across cell membranes, collapsing the ion gradients on which Gram-positive bacteria and coccidial parasites (Eimeria spp.) depend. In the rumen, this selective action reduces acetate- and hydrogen-producing bacteria, shifts fermentation towards propionate, lowers methane formation and reduces protein breakdown, which together improve feed efficiency. In poultry, monensin acts against the extracellular stages of Eimeria and is used for the prevention of coccidiosis.
For the purpose of this study, the market includes the value of monensin products sold for use in cattle and poultry, in all commercial physical forms: medicated premixes and Type A medicated articles incorporated into compound feed, as well as other forms such as granular products, liquid feed supplements, free-choice blocks and intraruminal continuous-release devices. Monensin used in fixed combinations with other approved feed additives is included at the value attributable to the monensin product.
The market excludes other ionophores (such as lasalocid, salinomycin, narasin, maduramicin and semduramicin), synthetic chemical coccidiostats, coccidiosis vaccines, phytogenic and other non-antibiotic feed additives, and the value of the compound feed into which monensin is incorporated.
Scope of the Study
The study quantifies the global monensin market in value terms and analyses it across the following segmentations:
By Livestock: Cattle, Poultry
By Physical Form: Premix, Others
By Region: North America (U.S., Canada, Mexico); Europe (Germany, U.K., France, Italy, Spain, Rest of Europe); Asia Pacific (China, India, Japan, Rest of Asia Pacific); Latin America (Brazil, Argentina, Rest of Latin America); Middle East & Africa (UAE, Saudi Arabia, South Africa, Rest of MEA)
Historic data covers 2022, 2023 and 2024; 2025 is the base year; and the forecast covers 2026–2032. Growth rates are expressed as the compound annual growth rate (CAGR) for 2026–2032. All values are presented in USD Million.
Research Objectives
To estimate the size of the global monensin market in 2025 and forecast its value to 2032.
To analyse the market by livestock and physical form, and to identify the largest and fastest-growing segments.
To assess regional and country-level demand across North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
To examine the regulatory status of monensin as a coccidiostat and ruminant feed additive in key jurisdictions and its effect on demand.
To evaluate the drivers, restraints, opportunities and trends shaping monensin use in cattle and poultry production.
To assess the effect of antibiotic-free production programmes, coccidial resistance and alternative coccidiosis control tools on monensin demand.
To review the role of monensin in enteric methane mitigation and sustainability strategies in cattle production.
To profile the competitive structure of the market and track key developments by leading suppliers from 2022 onwards.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansOverview of the Research Process
The study followed a structured process combining secondary research, primary research and analytical modelling. The process began with defining the product scope and segmentation, followed by collection of data on livestock populations, feed production, regulatory approvals and supplier activity. Market estimates were then built using both top-down and bottom-up approaches, cross-checked through data triangulation, and validated with industry participants before forecasts were prepared.
Secondary Research
Secondary research was used to build an understanding of the product, its applications and its regulatory environment, and to collect baseline data for market sizing. The main source types were:
Government and regulatory bodies: the U.S. Food and Drug Administration Center for Veterinary Medicine, the electronic Code of Federal Regulations, the European Commission's register of feed additives, the European Food Safety Authority, the European Medicines Agency, the Canadian Food Inspection Agency, India's Department of Animal Husbandry and Dairying, and national agriculture ministries.
Agricultural statistics: livestock inventories, slaughter numbers and meat and milk production from the USDA Foreign Agricultural Service and the Food and Agriculture Organization.
Industry associations: national and international feed manufacturing, poultry, beef and dairy associations, and animal health industry bodies.
Company sources: annual reports, regulatory filings, investor presentations, product labels and press releases of monensin suppliers and medicated feed manufacturers.
Scientific and trade literature: peer-reviewed studies on ionophore efficacy, coccidiosis and enteric methane, as well as feed and livestock trade journals.
Paid databases: trade, company and market databases covering animal health products and veterinary active ingredients.
Primary Research
Primary research was conducted through in-depth interviews with participants across the value chain to validate secondary findings and to gather qualitative insight on pricing, usage practices and outlook. On the supply side, respondents included product managers, regulatory affairs and commercial executives at monensin manufacturers, premix producers and distributors. On the demand side, respondents included feed mill managers, ruminant and poultry nutritionists, veterinarians, feedlot and dairy operators, and poultry integrators. The objectives were to verify inclusion rates and usage patterns by species, understand the split between premix and other forms, assess price trends, and test the assumptions behind the forecast.
Market Size Estimation
Top-down approach: The overall animal health and feed additive market was used as a starting point, and the share attributable to ionophores and to monensin in particular was estimated using supplier disclosures, regulatory information and expert input. The resulting global value was then allocated to regions, countries and segments.
Bottom-up approach: Country-level demand was estimated from livestock populations treated with monensin, typical inclusion rates and treatment durations, multiplied by average selling prices for each physical form. Country estimates were then aggregated to regional and global totals.
Data triangulation: The results of the two approaches were compared and reconciled. Differences were investigated through further secondary research and discussions with industry participants until a consistent set of estimates was reached.
Forecasting Methodology
Forecasts were developed for each country and segment by analysing historic trends together with the factors expected to affect future demand. The factors considered included projected cattle and poultry production, feedlot and dairy intensification, the regulatory status of monensin and competing products, adoption of antibiotic-free production programmes, coccidiosis control practices, price trends from generic competition, and macroeconomic conditions. Each factor was assessed for its direction and strength of impact over the short, medium and long term, and the resulting growth rates were applied to base-year values.
Base Year, Forecast Period and Currency
Assumptions and Limitations
Exchange rates are assumed to remain broadly stable over the forecast period, and values are expressed in nominal U.S. dollars.
The regulatory status of monensin in the major markets is assumed to remain unchanged over the forecast period, apart from developments already announced.
No major disruption of global livestock production, such as a widespread animal disease event, is assumed beyond normal cyclical variation.
Several suppliers are privately held and do not disclose sales by product; estimates for these companies rely on indirect indicators and expert input.
Pricing varies by contract, volume and format, and average selling prices used in the model are representative rather than exact.
Base Year
2025
Historical Period
2022 – 2024
Forecast Period
2026 – 2032
Primary Interviews
150+
Historical data (2022–2025) and forecast period (2025–2032)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansIntroduction
The global monensin market is consolidated at the level of active ingredient production and fragmented at the level of downstream feed products. Monensin is produced by fermentation, a capital-intensive process that requires proprietary strains and long operating experience, and product approvals are granted to individual sponsors in each country. As a result, a small number of companies control most of the world's supply. Elanco Animal Health, which developed monensin and introduced the Coban and Rumensin brands, remains the reference supplier. Huvepharma became the first generic supplier in the United States in 2019 and has since built a portfolio of combination approvals. Phibro Animal Health supplies monensin in Australia and New Zealand, and Chinese fermentation companies supply active ingredient to Asian markets.
Downstream, feed manufacturers, supplement producers and premix companies compete to formulate monensin into medicated feeds, blocks, liquid supplements and minerals. Competition centres on product reliability and quality, breadth of approved combinations and claims, technical service to nutritionists and veterinarians, supply security and, increasingly, price, as generic products gain acceptance. Evidence on sustainability outcomes, such as methane reduction, is becoming a further point of differentiation.
Key Player Positioning
Market Leaders
Elanco Animal Health (U.S.): The originator of monensin, with Rumensin for cattle and Coban and Elancoban for poultry, supported by the broadest set of combination approvals in the market. Elanco reported revenue of USD 4,715 million for FY2025, and Rumensin is among its five largest product families. Its strategy is to defend Rumensin through new combination approvals and sustainability positioning, as the product has no patent protection.
Huvepharma (Bulgaria): A privately held, vertically integrated producer with large fermentation capacity at its Biovet sites in Bulgaria and distribution in more than 90 countries. Its monensin portfolio includes Monovet 90 in the United States, Monovet premix in Canada, Coxidin in Europe and Monimax, a combination of monensin and nicarbazin. Revenue is not publicly disclosed. Huvepharma's strategy is to build combination labels around Monovet and expand in Latin America, Asia and Africa.
Challengers
Phibro Animal Health (U.S.): A medicated feed additive and nutritional specialty company that reported revenue of USD 1,518.1 million for FY2026 (year ended June 2026). Phibro markets PhibroMonensin in Australia and New Zealand and holds the U.S. approval for the combination of Rumensin with its V-Max (virginiamycin). Its acquisition of Zoetis's medicated feed additive portfolio in 2024 strengthened its position in feed additives.
Niche Players
Ridley USA (Alltech) (U.S.): A supplement manufacturer that received FDA approval in May 2026 for CRYSTALYX IONO-LYX R800, a monensin free-choice block for growing cattle on pasture. Revenue is not publicly disclosed.
ADM Animal Nutrition (U.S.): The animal nutrition business of Archer Daniels Midland, an approved sponsor of monensin free-choice blocks. ADM reported total revenue of USD 80,269 million for FY2025.
Purina Animal Nutrition (Land O'Lakes) (U.S.): An approved sponsor of monensin free-choice products, supplying monensin within its beef and dairy supplement range. Land O'Lakes reported revenue of about USD 16.8 billion for 2023.
Bio Agri Mix (Canada): A Canadian supplier of medicated feed premixes, including its Monensin Premix, listed in the CFIA's medicating ingredient brochure. Revenue is not publicly disclosed.
Shandong Shengli Bioengineering (China): A fermentation-based producer of veterinary active ingredients, including monensin, serving East, South and Southeast Asia. It is a joint venture involving China Animal Husbandry Industry, which reported revenue of CNY 6,205 million for FY2025.
Shandong Qilu King-Phar Pharmaceutical (China): A veterinary active ingredient producer listed as a supplier of monensin sodium. Revenue is not publicly disclosed.
Threat of New Entrants: Low
Fermentation-based production requires specialised strains, large capital investment and operating experience.
Approvals are product- and sponsor-specific, and generic entrants must demonstrate bioequivalence and manufacturing compliance, as shown by the first U.S. generic approval only in 2019.
Established suppliers benefit from long-standing customer relationships and extensive combination approvals.
Bargaining Power of Suppliers: Medium
Fermentation inputs such as carbohydrates, soybean products and energy are widely available commodities, but their prices are volatile.
Downstream premix producers and feed mills depend on a small number of monensin manufacturers, which gives those manufacturers bargaining power.
Bargaining Power of Buyers: High
Large poultry integrators, feedlot operators and feed manufacturers purchase in high volumes and negotiate on price.
The availability of generic monensin since 2019 gives buyers an alternative to the originator brand.
Nutritionists can switch between ionophores and other coccidiostats in rotation programmes.
Threat of Substitutes: Medium
Other ionophores such as lasalocid, salinomycin and narasin, as well as synthetic coccidiostats and vaccines, compete in poultry.
In cattle, alternatives for feed efficiency and methane reduction are emerging, but few match monensin's cost and evidence base.
Antibiotic-free programmes favour non-ionophore alternatives.
Intensity of Competitive Rivalry: Medium
The market is concentrated, with a few suppliers controlling most fermentation capacity.
Competition between the originator and generic suppliers is increasing, mainly on price and combination labels.
Rivalry is moderated by the regulatory barriers and limited number of approved products in each market.
Threat of New Entrants: Low; Fermentation know-how, capital intensity and product-specific approvals.
Bargaining Power of Suppliers: Medium; Commodity inputs, but concentrated monensin manufacturing.
Bargaining Power of Buyers: High; Large integrators and feed mills, generic alternatives available.
Threat of Substitutes: Medium; Other ionophores, chemical coccidiostats, vaccines and alternative additives.
Competitive Rivalry: Medium; Few suppliers, growing originator–generic price competition.
Market estimates by geography (2032)
InsightAsia Pacific leads with $82.87M by 2032.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2022 | 2025 | 2032 | CAGR | SHARE |
|---|---|---|---|---|---|
| North America | $48.07M | $59.44M | $72.52M | 4.2% | 28% |
| Europe | $19.47M | $23.57M | $28.05M | 3.7% | 11% |
| Asia Pacific | $46.13M | $61.43M | $82.87M | 6.0% | 32% |
| Latin America | $34.12M | $44.70M | $58.76M | 5.6% | 23% |
| Middle East & Africa | $9.30M | $12.14M | $15.55M | 5.3% | 6% |
| Total | $157.10M | $201.28M | $257.76M | 5.1% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansTotal Market Size
$257.76M
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Cattle | $145.47M | 5.4% | 56% |
| Poultry | $112.29M | 4.6% | 44% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.
Analytical insights on Monensin Market covering market dynamics, competitive landscape, and strategic outlook.
The Monensin Market market is projected to reach $257.76M by 2032, growing at 5.1% CAGR. The Cattle segment holds the largest share.
The global monensin market is expected to grow at a CAGR of 5.07% over 2026–2032. Demand depends on the size and intensity of cattle and poultry production, the economics of feed efficiency, the regulatory treatment of ionophores, and the competitive position of monensin relative to other coccidiosis and rumen-modification tools. This chapter assesses these forces. The impact scores in the growth factor analysis below are analyst assessments, rated on a scale of 1 (minimal impact) to 10 (very strong impact) for each period.
Growing Poultry Production and the Cost of Coccidiosis
Poultry is the fastest-expanding source of animal protein worldwide. The USDA Foreign Agricultural Service projected global chicken meat production at a record 110.7 million tonnes in 2026, an increase of 2.5% on the previous year, led by China, while the FAO expects poultry to remain the main driver of global meat output growth. Every additional broiler flock housed on litter carries a risk of coccidiosis, which is caused by Eimeria parasites and remains the most economically important parasitic disease of chickens. A widely cited 2020 study by Blake and colleagues estimated the global cost of coccidiosis in chickens at more than GBP 10 billion a year at 2016 prices, through mortality, poor weight gain, reduced feed conversion and treatment. In-feed anticoccidials remain the main means of control in conventional broiler production, and monensin, used since the early 1970s, is one of the most widely used ionophores in starter and grower diets and in shuttle and rotation programmes. Growth in housed broiler and turkey numbers in Asia, Latin America and the Middle East therefore translates directly into demand for monensin.
Feed Efficiency Economics in Beef and Dairy Cattle
Feed is the largest cost in cattle finishing and dairy production, and monensin is one of the few additives with a long record of improving feed efficiency. A 2012 meta-analysis by Duffield and colleagues in the Journal of Animal Science found that monensin improved feed efficiency in beef cattle by about 6.4%, with a 2.5% increase in average daily gain and a 3% reduction in dry matter intake. In dairy cows, monensin improves energy status around calving and is approved in the United States for increased milk production efficiency. Because these benefits are measurable in cost per kilogram of gain or per litre of milk, monensin is a standard ingredient in feedlot rations in the United States, Brazil, Argentina, Australia and South Africa, and its value rises when grain and protein prices are high. The expansion of confinement and semi-confinement finishing in Brazil, Mexico and China further widens the base of cattle that receive formulated rations containing monensin.
Regulatory Position of Ionophores under Antimicrobial Stewardship
Restrictions on antibiotics in animal feed have focused on medically important antimicrobials, and this has generally protected monensin. In the United States, FDA Guidance for Industry #213 removed growth promotion claims for medically important antimicrobials from 2017 and placed their feed use under the Veterinary Feed Directive, but ionophores were outside its scope because they are not used in human medicine. Monensin therefore remains available over the counter, and FDA's annual antimicrobial sales reports treat ionophores separately from medically important classes. China's Ministry of Agriculture and Rural Affairs Announcement No. 194 ended the use of growth-promoting antibiotic feed additives from 2020, while coccidiostats, including monensin premixes, were moved into the veterinary drug approval system rather than withdrawn. In the European Union, monensin sodium remains authorised as a coccidiostat for poultry under Regulation (EC) No 1831/2003; the authorisation of Huvepharma's Coxidin was renewed in 2026. This position has made monensin a durable tool as other in-feed antibiotics have been withdrawn.
Enteric Methane Reduction and Sustainability Commitments
Livestock producers, meat processors and food retailers are under growing pressure to reduce greenhouse gas emissions, and enteric methane from cattle is the largest single source in beef and dairy supply chains. Monensin is one of the few widely approved, low-cost feed additives with a substantial evidence base on methane. A 2024 meta-analysis by Cooke and colleagues found that monensin reduced methane production in beef cattle by about 15%, while a 2023 meta-analysis of dairy studies reported reductions of about 5% at typical inclusion rates. Although methane reduction is not an approved label claim, suppliers such as Elanco cite these effects in their sustainability positioning, and the improvement in feed efficiency also lowers emissions per kilogram of product. As carbon accounting programmes and supply chain emission targets develop, the value of monensin to producers is expected to rise.
Intensification of Livestock Production in Asia Pacific and Latin America
Asia Pacific is the fastest-growing region, with a CAGR of 6.14%, and Latin America follows at 5.62%. Investment in large-scale feedlots, integrated poultry operations and commercial dairies in China, India, Southeast Asia, Brazil and Mexico moves animals from traditional systems into formulated feed, where monensin can be included. Suppliers that build local registration files, premix partnerships and technical service capability in these markets can capture a large share of new demand.
Methane Mitigation and Sustainability-Linked Value
The growing evidence that monensin reduces enteric methane creates an opportunity to position the product within carbon reduction programmes, supply chain sustainability schemes and potential future carbon credit methodologies for feed additives. Monensin can be combined with newer methane inhibitors and with other feed additives, which allows suppliers to offer integrated feed-efficiency and emission-reduction programmes to large beef and dairy customers.
New Delivery Formats and Combination Approvals
Approvals for free-choice blocks, liquid supplements and combinations with other feed additives extend monensin into pasture, stocker and heifer-rearing systems where daily hand-feeding is impractical. In May 2026, the FDA approved a monensin free-choice block for growing cattle on pasture, and combination approvals in 2023–2025 extended monensin use alongside chlortetracycline, virginiamycin, lubabegron and melengestrol acetate. These formats support the Others segment, which is expected to grow at a CAGR of 6.08%, faster than premix.
Toxicity to Non-Target Species and Feed Safety Risks
Monensin is highly toxic to horses and other equines, and also to dogs, at concentrations that are safe for cattle and poultry. Labels in the United States must warn against allowing equines access to feed containing monensin, and accidental contamination continues to cause losses. In September 2024, nearly 70 horses at a rodeo stock company in Oklahoma died after eating feed from a Kansas mill contaminated with monensin, and in October 2024 a super-potent calf starter was recalled after calf deaths, leading to an FDA warning letter to the manufacturer in June 2025. In 2024, the European Union suspended the Kexxtone monensin bolus for dairy cows after regurgitated devices poisoned dogs. Such incidents increase compliance and liability costs for feed mills, may lead some mills to limit monensin handling, and can delay or narrow new product approvals.
Antibiotic-Free Production Programmes and Regional Restrictions
Consumer-facing claims such as "No Antibiotics Ever" in U.S. poultry treat ionophores as antibiotics, so flocks raised under these programmes rely on chemical coccidiostats, vaccines and botanicals instead of monensin. Similar retailer and export-market requirements exist in other countries. In the European Union, monensin cannot be used as a growth promoter in cattle, which limits ruminant demand to authorised veterinary uses. These factors cap the addressable market in several high-value segments.
Coccidial Resistance and Generic Price Pressure
Decades of ionophore use have reduced the sensitivity of some Eimeria field populations; EFSA noted signs of resistance in its 2024 assessment of monensin for poultry. Producers respond with rotation and shuttle programmes and vaccines, which reduce the number of grow-outs in which monensin is used. In parallel, the absence of patent protection for Rumensin and the entry of generic monensin since 2019 have increased price competition, which slows value growth relative to volume.
Integrated Coccidiosis Control Programmes
Poultry producers increasingly combine ionophores, chemical anticoccidials and live vaccines in shuttle and rotation programmes, including bio-shuttle programmes that use vaccination in the starter phase and an ionophore later in the grow-out. This trend preserves a role for monensin while reducing its use per flock in some markets.
Concentrated Fermentation Supply
Monensin is produced by fermentation, and global supply depends on a small number of large fermentation sites in the United States, Bulgaria and China. Capacity decisions, energy costs and environmental compliance at these sites affect availability and pricing, and the concentration of supply is a risk for feed manufacturers that rely on a single source.
Tighter Feed Mill Safety and Traceability
Following contamination incidents, regulators and feed manufacturers are placing greater emphasis on equipment cleanout, flushing and sequencing, batch traceability and automated dosing controls. Under the U.S. preventive controls rule for animal food (21 CFR Part 507), mills must identify and control such hazards. These measures improve safety but add cost and complexity for mills handling monensin.
Cyclical Pressure on Cattle Numbers
The USDA Foreign Agricultural Service projected global beef production at 61.6 million tonnes in 2026, down 1.1% from the previous year, with lower output expected in Brazil, the United States, China, the European Union and Australia. Herd rebuilding in major beef producers reduces the number of cattle on feed in the short term, which moderates near-term growth in cattle demand before herds recover later in the forecast period.
The monensin value chain comprises four main stages, from fermentation inputs to livestock producers.
Raw materials and inputs: Monensin is produced by submerged fermentation of Streptomyces cinnamonensis. Key inputs are carbohydrate sources such as glucose, starch or corn derivatives; oils and protein sources such as soybean oil and soybean meal; mineral salts; process water; and energy. Proprietary high-yield production strains and fermentation know-how are critical inputs.
Manufacturing: Fermentation is followed by recovery and drying of the monensin-containing product, either as a dried fermentation product or as purified monensin sodium. This is then standardised and formulated into Type A medicated articles and premixes on carriers, or into granular products, liquid supplements, blocks and intraruminal devices. Production is regulated under veterinary drug and feed additive rules and is concentrated in a few facilities in the United States, Bulgaria and China.
Distribution and channels: Products reach users through direct sales to large integrators and feed manufacturers, through animal health distributors, through premix and vitamin-mineral companies, and through veterinarians and nutritionists who specify rations. Feed mills incorporate monensin into Type B and Type C medicated feeds and supplements.
End users: Feedlots, stocker and pasture operations, dairy farms and heifer-rearing units in the cattle sector, and broiler, pullet and turkey producers in the poultry sector. Large integrated companies account for a significant share of purchasing.
North America
In the United States, monensin is approved as a new animal drug, and its conditions of use in feed are set out in 21 CFR 558.355. Approved Type A medicated articles are sold over the counter because ionophores are not medically important antimicrobials; combinations containing a medically important drug, such as chlortetracycline or virginiamycin, require a Veterinary Feed Directive under 21 CFR 558.6. Feed manufacturing is subject to the FDA's current good manufacturing practice and preventive controls requirements for animal food under 21 CFR Part 507. In Canada, monensin products are authorised by Health Canada's Veterinary Drugs Directorate, and their use in feed is set out in the Canadian Food Inspection Agency's Compendium of Medicating Ingredient Brochures.
Europe
The European Union banned antibiotics as growth promoters from 1 January 2006. Monensin sodium remains authorised as a coccidiostat feed additive for poultry under Regulation (EC) No 1831/2003, through holder-specific authorisations such as Commission Implementing Regulation (EU) 2026/532 renewing Coxidin. Veterinary medicinal products, including the Kexxtone intraruminal device for dairy cows, fall under Regulation (EU) 2019/6, and medicated feed falls under Regulation (EU) 2019/4. Maximum residue limits are set under Commission Regulation (EU) No 37/2010, and maximum levels of unavoidable carry-over of coccidiostats into non-target feed and food are set under Directive 2002/32/EC and Commission Regulation (EC) No 124/2009.
Asia Pacific
In China, MARA Announcement No. 194 ended growth-promoting uses of antibiotic feed additives from 2020 and transferred coccidiostats into the veterinary drug approval system. In India, monensin sodium premixes appear on the Department of Animal Husbandry and Dairying's consolidated list of animal feed additives permitted for import, with label warnings for laying hens and equines. In Australia, monensin products are registered by the Australian Pesticides and Veterinary Medicines Authority, and in New Zealand, the Ministry for Primary Industries opened a reassessment of monensin products under the Agricultural Compounds and Veterinary Medicines Act in October 2024. Japan applies a positive list system for residues in food.
Latin America and Middle East & Africa
Brazil's Ministry of Agriculture and Livestock regulates veterinary products and feed additives; its Normative Instruction No. 1 of 2020 prohibited tylosin, lincomycin and tiamulin as performance enhancers, but did not restrict ionophores. Across Latin America and the Middle East & Africa, monensin products are registered with national veterinary authorities, and many countries reference Codex Alimentarius maximum residue limits for monensin, which are based on evaluations by the Joint FAO/WHO Expert Committee on Food Additives.
Aug 2022: Huvepharma; Product registration; Received Canadian authorisation for Monovet monensin premix (200 g/kg), later listed in the CFIA medicating ingredient brochure.
May 2023: Huvepharma; Regulatory approval; Obtained FDA approval for use of Monovet 90 in combination with chlortetracycline (Pennchlor) in beef cattle.
Dec 2023: Elanco Animal Health / Pharmgate; Regulatory approval; FDA approved the combination of Rumensin with Pennchlor for dairy and beef replacement heifers.
Mar 2024: Huvepharma; Regulatory assessment; EFSA published a favourable opinion on the safety and efficacy of Coxidin (monensin sodium) for chickens and turkeys.
Apr 2024: Phibro Animal Health / Zoetis; Acquisition; Phibro agreed to acquire Zoetis's medicated feed additive portfolio for USD 350 million, covering 37 product lines and six manufacturing sites.
May 2024: Elanco Animal Health; Product suspension; The European Commission suspended the Kexxtone monensin intraruminal device for dairy cows after cases of poisoning in dogs, followed by a product recall.
Oct 2024: Elanco Animal Health, Phibro Animal Health and other registrants; Regulatory review; New Zealand's Ministry for Primary Industries opened a reassessment of 23 registered monensin products.
Oct 2024: Huvepharma; Regulatory approval; FDA extended approval of Monovet 90 with Pennchlor to replacement beef and dairy heifers.
Oct 2024: Phibro Animal Health; Acquisition; Completed the acquisition of Zoetis's medicated feed additive portfolio.
Nov 2024: Elanco Animal Health; Regulatory approval; FDA approved combinations of Experior with Rumensin and MGA, with and without Tylan, for finishing heifers.
Apr 2025: Phibro Animal Health / Elanco Animal Health; Regulatory approval; FDA approved the combination of Rumensin with V-Max (virginiamycin) for cattle fed in confinement for slaughter.
Mar 2026: Huvepharma; Regulatory approval; Commission Implementing Regulation (EU) 2026/532 renewed the authorisation of Coxidin for chickens and turkeys and extended it to turkeys reared for breeding.
May 2026: Ridley USA (Alltech); Product launch; FDA approved CRYSTALYX IONO-LYX R800, a monensin free-choice block for growing beef cattle and replacement heifers on pasture.
Political
Government food security strategies in the Middle East, Asia and Africa support domestic poultry and dairy expansion.
Trade measures affecting meat and live cattle, such as U.S. suspensions of Mexican cattle imports in 2024–2025, change where cattle are finished.
National antimicrobial resistance action plans shape the regulatory treatment of feed antibiotics.
Economic
High feed costs raise the value of feed efficiency improvements delivered by monensin.
Rising incomes in emerging economies drive demand for poultry and beef.
Generic supply and buyer consolidation exert downward pressure on prices.
Social
Consumer interest in antibiotic-free meat reduces ionophore use in some poultry programmes.
Animal welfare expectations favour effective coccidiosis prevention to reduce disease in flocks.
Public concern over horse and pet poisonings from contaminated feed raises scrutiny of feed safety.
Technological
Improved fermentation strains and process control raise yields and lower production costs.
Granulation, liquid and block technologies widen delivery options.
Automated batching and cleanout systems in feed mills reduce cross-contamination risk.
Environmental
Monensin's effect on enteric methane supports its role in emission reduction programmes.
Improved feed efficiency reduces land, water and feed use per unit of meat or milk.
Residues in manure and their environmental fate are subject to regulatory assessment.
Legal
Product-specific approvals and maximum residue limits govern use in each market.
Liability for contamination incidents can be substantial for feed manufacturers.
Periodic reauthorisations, such as EU renewals and New Zealand's reassessment, can change permitted uses.
Profiles of 32 companies operating in the Monensin Market market, including revenue, employee count, and market positioning where available.
Showing 32 of 32 companies
3 interactive charts drawn from the Monensin Market dataset — market size, regional splits and each segment breakdown. Open one to read its full data table and download it.
Global Monensin Market By Physical Form
Global Monensin Market By Livestock
Global Monensin Market By Region
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Historical performance and future projections (2020–2030, USD Billion)
Market Size (USD Million)
